Clinical Trials
33 trialsTo Explore the Optimal Therapeutic Window for Imatinib in the Adjuvant Treatment of Intermediate and High-risk Gastrointestinal Stromal Tumors
First Affiliated Hospital, Sun Yat-Sen University
Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
University of California, San Diego
PEMIGIST
Dana-Farber Cancer Institute
A Novel Two-Tooth Clip for ESD and EFTR of GIST
Affiliated Hospital to Academy of Military Medical Sciences
iCaRe2
University of Nebraska
SAVE-GEJ
Peking University People's Hospital
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Peking University Cancer Hospital & Institute
ATEZOGIST
Centre Leon Berard
Long-term Survivorship Challenges of Advanced/Metastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment: an Observational Study
The Netherlands Cancer Institute
GIST
Asan Medical Center
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Asan Medical Center
GIST Oral Paclitaxel(Liporaxel)
Asan Medical Center
Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.
Asan Medical Center
Development of a Multimodal AI System for GIST Management
Hebei Medical University
SUR-CAN
Centre Oscar Lambret
PALANGI3
Centre Oscar Lambret
Imatinib TDM in GIST
University of Kentucky
GIST
National Health Research Institutes, Taiwan
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
M.D. Anderson Cancer Center
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
Stanford University
reGISTTry
Universität Duisburg-Essen
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Sarcoma Alliance for Research through Collaboration
ZINCLO-HAND
Gazi University
AXAGIST
Maria Sklodowska-Curie National Research Institute of Oncology
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
University of Miami
CYCLIGIST
Institut Bergonié
PATHFINDERS
Universität Duisburg-Essen
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Asan Medical Center
CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study
Huazhong University of Science and Technology
A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment
Peking University
Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
Huazhong University of Science and Technology
PARTNER
Azienda Ospedaliera di Padova